LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

Home・Aandelen Lijst・Ovid therapeutics Inc

Ovid therapeutics Inc

Gesloten

SectorGezondheidszorg

1.62 1.89

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.54

Max

1.62

Belangrijke statistieken
By Trading Economics
Inkomsten	-7.5M -12M
Verkoop	-6.1M 132K
Winstmarge	-9,210.606
Werknemers	23
EBITDA	-7.6M -12M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+197.45% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	32M 128M
Vorige openingsprijs	-0.27
Vorige sluitingsprijs	1.62

Nieuwssentiment

By Acuity

19%

81%

36 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

0.275 / 0.33 Steun & Weerstand

Ovid therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 dec 2025, 22:13 UTC

Winsten

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

9 dec 2025, 21:40 UTC

Winsten

GameStop Sales Fall as Collectibles Remain Only Bright Spot

9 dec 2025, 18:51 UTC

Acquisities, Fusies, Overnames

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

9 dec 2025, 16:57 UTC

Belangrijke Marktbewegers

Clear Secure Rises on Medicare Identity Verification Contract

9 dec 2025, 23:46 UTC

Marktinformatie

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

9 dec 2025, 23:46 UTC

Acquisities, Fusies, Overnames

Legend Holdings Stake in Lenovo Now at 32.34%

9 dec 2025, 23:45 UTC

Acquisities, Fusies, Overnames

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

9 dec 2025, 23:44 UTC

Acquisities, Fusies, Overnames

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

9 dec 2025, 23:43 UTC

Acquisities, Fusies, Overnames

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

9 dec 2025, 23:43 UTC

Acquisities, Fusies, Overnames

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

9 dec 2025, 23:35 UTC

Marktinformatie

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

9 dec 2025, 22:42 UTC

Winsten

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

9 dec 2025, 21:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

9 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

9 dec 2025, 21:48 UTC

Marktinformatie

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

9 dec 2025, 21:36 UTC

Winsten

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

9 dec 2025, 21:36 UTC

Winsten

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

9 dec 2025, 21:36 UTC

Winsten

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

9 dec 2025, 21:36 UTC

Winsten

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

9 dec 2025, 21:36 UTC

Winsten

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

9 dec 2025, 20:28 UTC

Marktinformatie

Oil Futures Decline for Second Straight Session -- Market Talk

9 dec 2025, 20:27 UTC

Acquisities, Fusies, Overnames

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

9 dec 2025, 20:27 UTC

Acquisities, Fusies, Overnames

Teck Reports Voting Results From Special Meeting of Hldrs

9 dec 2025, 20:26 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

9 dec 2025, 20:21 UTC

Marktinformatie

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

9 dec 2025, 19:52 UTC

Winsten

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

9 dec 2025, 19:17 UTC

Winsten

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

9 dec 2025, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

9 dec 2025, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

9 dec 2025, 17:11 UTC

Winsten

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Peer Vergelijking

Prijswijziging

Ovid therapeutics Inc Prognose

Koersdoel

By TipRanks

197.45% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4.67 USD 197.45%

Hoogste 7 USD

Laagste 2 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ovid therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan Ovid therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

0.275 / 0.33Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

36 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.